title: The efficacy and safety of maraviroc addition to a stable antiretroviral regimen in subjects with suppressed plasma HIV-RNA is not influenced by age.
abstract: There are few data about the immunovirological efficacy, safety/tolerability, and durability of maraviroc (MVC) addition to aging patients on suppressive antiretroviral therapy (cART) and undetectable viral load (<50 copies/ml). The aging population is underrepresented in most HIV clinical trials. This study included 80 patients aged ≥50 years and 161 aged <50 years and showed that after 48 weeks of treatment, there was no between-group differences in the median increase of CD4(+) T cells or the virological suppression rate. Safety and tolerability were also comparable. In multivariable analysis, the effect of age was not modified and was independent of the response to MVC. An immunological recovery of ≥100 CD4(+) T cells was significantly less common in those with a longer HIV history (≥15 years) (OR 0.43; p=0.016) or having <200/mm(3) CD4(+) T cells at MVC initiation (OR 0.27; p=0.004). Meanwhile, achieving a CD4/CD8 ratio ≥0.5 at week 48 was less likely in those with CD4(+) T cell counts <200 at MVC initiation (OR 0.09; p<0.0001) or with a previous AIDS event (OR 0.43; p=0.028). In summary, the immunovirological efficacy, safety/tolerability, and durability of MVC addition in patients virologically suppressed were independent of the patient's age at treatment onset.
authors.affiliation: 1 Hospital San Pedro-CIBIR , Logroño, Spain .
authors.forename: José-Ramón
authors.initials: JR
authors.lastname: Blanco
authors.affiliation: 2 Hospital Ramón y Cajal-IRYCIS , Madrid, Spain .
authors.forename: David
authors.initials: D
authors.lastname: Arroyo-Manzano
authors.affiliation: 3 Hospital Clinic Barcelona , Barcelona, Spain.
authors.forename: John F
authors.initials: JF
authors.lastname: Rojas-Liévano
authors.affiliation: 4 Hospital Universitari Vall d'Hebrón , Barcelona, Spain .
authors.forename: Manuel
authors.initials: M
authors.lastname: Crespo
authors.affiliation: 5 Hospital Universitari Germans Trias i Pujol , Badalona, Spain .
authors.forename: Isa
authors.initials: I
authors.lastname: Bravo
authors.affiliation: 6 Hospital Universitario Virgen de las Nieves , Granada, Spain .
authors.forename: Juan
authors.initials: J
authors.lastname: Pasquau
authors.affiliation: 7 Consorcio Hospital General Universitario de Valencia , Valencia, Spain .
authors.forename: Miguel
authors.initials: M
authors.lastname: Garcia Del Toro
authors.affiliation: 5 Hospital Universitari Germans Trias i Pujol , Badalona, Spain .
authors.forename: Cristina
authors.initials: C
authors.lastname: Herrero
authors.affiliation: 8 Hospital Reina Sofía-IMIBIC , Córdoba, Spain .
authors.forename: Antonio
authors.initials: A
authors.lastname: Rivero
authors.affiliation: 9 Hospital Ramón y Cajal-IRYCIS , Madrid, Spain .
authors.forename: Santiago
authors.initials: S
authors.lastname: Moreno
authors.affiliation: 5 Hospital Universitari Germans Trias i Pujol , Badalona, Spain .
authors.forename: Josep Maria
authors.initials: JM
authors.lastname: Llibre
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D065100:CCR5 Receptor Antagonists / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D003510:Cyclohexanes / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D006678:HIV / Q000235:genetics; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy / Q000821:virology; D006801:Humans; D000077592:Maraviroc; D008875:Middle Aged; D015999:Multivariate Analysis; D012367:RNA, Viral / Q000097:blood; D012189:Retrospective Studies; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D012367:RNA, Viral; D014230:Triazoles; D000077592:Maraviroc